Sowell Financial Services LLC Reduces Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• Sowell Financial Services LLC has reduced its holdings in Thermo Fisher Scientific Inc. by 24.7%, owning 4,214 shares worth approximately $1.7 million after selling 1,383 shares.
• Despite Sowell's decrease in shares, several other institutional investors, including Mondrian Investment Partners LTD and Foresight Group Ltd, significantly increased their positions in Thermo Fisher during the same period.
• Thermo Fisher recently announced a quarterly dividend of $0.43 per share, with an annualized yield of 0.4%, and reported a quarterly earnings per share of $5.36, exceeding analysts' expectations.

Sowell Financial Services LLC decreased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 24.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,214 shares of the medical research company's stock after selling 1,383 shares during the period. Sowell Financial Services LLC's holdings in Thermo Fisher Scientific were worth $1,709,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Mondrian Investment Partners LTD increased its position in shares of Thermo Fisher Scientific by 146.1% in the 1st quarter. Mondrian Investment Partners LTD now owns 214,506 shares of the medical research company's stock worth $106,738,000 after purchasing an additional 127,357 shares during the last quarter. Foresight Group Ltd Liability Partnership increased its position in shares of Thermo Fisher Scientific by 3,242.7% in the 1st quarter. Foresight Group Ltd Liability Partnership now owns 58,497 shares of the medical research company's stock worth $29,113,000 after purchasing an additional 56,747 shares during the last quarter. Advisors Capital Management LLC increased its position in shares of Thermo Fisher Scientific by 6.7% in the 1st quarter. Advisors Capital Management LLC now owns 127,011 shares of the medical research company's stock worth $63,201,000 after purchasing an additional 7,967 shares during the last quarter. Ilmarinen Mutual Pension Insurance Co increased its position in shares of Thermo Fisher Scientific by 5.3% in the 1st quarter. Ilmarinen Mutual Pension Insurance Co now owns 67,300 shares of the medical research company's stock worth $33,488,000 after purchasing an additional 3,400 shares during the last quarter. Finally, New England Research & Management Inc. increased its position in shares of Thermo Fisher Scientific by 28.6% in the 2nd quarter. New England Research & Management Inc. now owns 2,548 shares of the medical research company's stock worth $1,033,000 after purchasing an additional 567 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Trading Down 1.1%

Shares of NYSE:TMO opened at $474.54 on Tuesday. The company has a 50 day moving average of $472.99 and a 200-day moving average of $448.55. The firm has a market cap of $179.19 billion, a P/E ratio of 27.45, a P/E/G ratio of 2.56 and a beta of 0.75. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $623.77. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. During the same period in the prior year, the business posted $5.37 EPS. The business's revenue for the quarter was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio is currently 9.95%.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on TMO shares. Evercore ISI dropped their target price on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a research report on Tuesday, July 8th. UBS Group boosted their price objective on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a research report on Thursday, July 24th. Wells Fargo & Company lowered their price objective on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a research report on Thursday, July 24th. Barclays raised shares of Thermo Fisher Scientific from an "equal weight" rating to an "overweight" rating and boosted their price objective for the company from $490.00 to $550.00 in a research report on Thursday, September 11th. Finally, HSBC reaffirmed a "hold" rating and set a $510.00 price objective on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Sixteen investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $588.35.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the transaction, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Joseph R. Holmes sold 385 shares of the company's stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the transaction, the chief accounting officer owned 2,319 shares in the company, valued at approximately $1,142,408.97. This represents a 14.24% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 30,066 shares of company stock worth $14,182,963. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.